Developing the next generation of medical devices and consumer products to leverage the potential of photosensitisers.
Multiple light-activated drugs have been developed. They have shown effectiveness in treating a range of diseases. However, these light-activated drugs have had limited impact on global and consumer health due to the delivery of light to these drugs in the body
Using microscale engineering we use functional LED and sensor technology to activate and measure light active drugs for therapeutics, diagnostics and consumer products. Our first therapeutic focus is delivering photoactivation therapy for the treatment of viral and bacterial infections.
Our first market niche is mechanically ventilated patents with viral or bacterial pneumonia, which is responsible for 30,000 deaths and worth an estimated £10 Million within the UK each year. Our future market in pneumonia and sepsis are annually worth an estimated $30bn.
- Alastair Kirby, CEO
- Dr Christopher Russell, CTO.
UN Sustainable Development Goals
Want to connect with Vivisco?
Fill out the form below and we’ll send an introduction email to you and the founders.
Please note that if you would also like to connect with other King’s20 Ventures, we ask that you fill out the form at the bottom of the page each time so we can send separate intro emails.
As always, we respect your privacy and will not contact you without your consent or share your details.